The radiotherapy market size is estimated at USD 9.14 billion in 2026, and is expected to reach USD 12.87 billion by 2031, at a CAGR of 7.08% during the forecast period (2026-2031). This report Segments the Industry Into by Product (Radiotherapy Equipment, and More), Technology (Photon Beam Therapy, and More), Therapy Type (External Beam Radiation Therapy, and More), Application (Breast Cancer, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Systemic agents broaden access where machine capacity is saturated, especially for metastatic disease. Lutathera sales climbed 28% in 2025 as label extensions in Japan and Australia came online. Internal brachytherapy stabilizes nearly 8% of therapy revenue, as isotope logistics and SBRT competition cap further growth. Over the forecast window, external-beam volumes stay high but see share erosion as radiopharmaceuticals secure a larger metastatic niche.
Intensity-modulated radiotherapy captured 31.73% of the technology revenue in 2025, reflecting its status as a standard of care for prostate and head-and-neck cancers. Proton beam therapy, while smaller, is expanding at an 8.38% CAGR, assisted by Chinese provincial funding for eight new centers in 2025. Cost declines from single-room designs, now priced near USD 25 million, are drawing community hospitals into the modality.
Volumetric-modulated arc therapy reduces session times to two minutes, enabling high-throughput centers to manage rising caseloads more efficiently. Image-guided platforms hold 28% of revenue, bolstered by American College of Radiology rules that require daily imaging for stereotactic treatments. Carbon-ion therapy remains confined to a handful of Japanese and German sites due to the high capital costs of approximately USD 80 million. Overall, software-centric upgrades dominate budgets as facilities extract more productivity from legacy hardware.
The Asia-Pacific region is the fastest-growing, with a 9.01% CAGR. India’s USD 1.2 billion scheme to install 150 linacs aims to halve the nine-week waiting lists. Japan, South Korea, and Australia are bolstering reimbursement and workforce pipelines to support carbon-ion and proton services.
Europe accounts for 28% of revenue but faces budget constraints. Germany upgraded outpatient tariffs, shifting 18% of head-and-neck cases to day-clinic settings. The United Kingdom’s static tariff keeps proton reimbursements at 60% of cost, restraining private investment. France invested EUR 180 million to swap cobalt units for linacs, raising average dose conformality.
The Middle East and Africa together hold 6% share, dominated by Gulf Cooperation Council procurement. Saudi Arabia plans to finance eight linacs in 2025, aiming to reach four machines per million inhabitants by 2030. South America sits at a 4.5% share, with Brazil installing 12 linacs despite macroeconomic volatility.
Global Radiotherapy Market Trends and Insights
Precision-Medicine Push for Sub-Millimeter Dose Delivery
Image-guided platforms that integrate cone-beam CT and real-time tumor tracking now support daily adaptive replanning, reducing healthy-tissue margins by half and allowing safe dose escalation.Early clinical data from MR-linac installations have reported 92% local control rates in oligometastatic liver lesions, representing a double-digit improvement over historical CT-guided protocols. International standards are also stricter: IEC 60601-2-64 requires an isocenter accuracy of less than 2 mm for stereotactic systems, prompting upgrades across 40% of the installed base by 2027. Proton systems now ship with pencil-beam scanning at 2 mm spot sizes, helping pediatric centers spare cognitive structures during cranial treatments. Commissioning these high-precision units, however, is lengthened when physicist vacancies persist, thereby prolonging go-live timelines.Reimbursement Expansion for Outpatient RT Procedures
In January 2025, the Centers for Medicare & Medicaid Services equalized payment for outpatient stereotactic body radiotherapy with hospital-based delivery, releasing an estimated USD 420 million in annual facility fees to freestanding centers. Private insurers quickly matched policy; Anthem added lung SBRT coverage for ambulatory surgery centers two months later, influencing 14 million covered lives. Germany followed by adding intensity-modulated radiotherapy for head-and-neck cancer to its outpatient catalog, shifting almost one-fifth of cases to day-clinic settings within half a year. These moves are not uniform, as the United Kingdom retained older tariffs that reimburse proton therapy at just 60% of cost, damping investment. Japan’s 12% boost in carbon-ion therapy payments likewise highlights reimbursement as a decisive lever for technology adoption.Linac & Proton-Room CAPEX Squeeze Amid Higher WACC
Weighted-average cost of capital rose from 5.2% in 2023 to 7.8% in 2025, stretching proton-suite payback periods to 12 years and prompting deferrals across Europe and Latin America. One leading Spanish hospital chain canceled a Madrid installation as financing costs made debt service exceed 40% of projected revenue. A U.S. survey found that 38% of community sites are delaying linac replacements, pushing the average equipment age to 11 years and increasing downtime. Vendors now offer decade-long leases that convert capital costs to operating expenses, but uptake remains modest.Other drivers and restraints analyzed in the detailed report include:
- AI-Driven Adaptive Planning Slashing Workflow Time
- FLASH & Ultra-High-Dose-Rate Proof-Of-Concept Successes
- Skilled Dosimetrist/Medical-Physicist Shortages
Segment Analysis
External beam radiotherapy led the radiotherapy market, accounting for 82.11% of the revenue share in 2025. Its broad tumor applicability and established infrastructure keep utilization high, yet treatment compression through hypofractionation moderates revenue growth. Systemic radiotherapy is projected to post a 7.86% CAGR to 2031, buoyed by the commercial success of Lutetium-177 agents such as Pluvicto, which secured expanded Medicare coverage at USD 42,500 per treatment. External-beam platforms are answering through AI-enabled adaptive workflows that reduce planning time to 52 minutes, allowing sites to accommodate higher patient volumes without adding rooms.Systemic agents broaden access where machine capacity is saturated, especially for metastatic disease. Lutathera sales climbed 28% in 2025 as label extensions in Japan and Australia came online. Internal brachytherapy stabilizes nearly 8% of therapy revenue, as isotope logistics and SBRT competition cap further growth. Over the forecast window, external-beam volumes stay high but see share erosion as radiopharmaceuticals secure a larger metastatic niche.
Intensity-modulated radiotherapy captured 31.73% of the technology revenue in 2025, reflecting its status as a standard of care for prostate and head-and-neck cancers. Proton beam therapy, while smaller, is expanding at an 8.38% CAGR, assisted by Chinese provincial funding for eight new centers in 2025. Cost declines from single-room designs, now priced near USD 25 million, are drawing community hospitals into the modality.
Volumetric-modulated arc therapy reduces session times to two minutes, enabling high-throughput centers to manage rising caseloads more efficiently. Image-guided platforms hold 28% of revenue, bolstered by American College of Radiology rules that require daily imaging for stereotactic treatments. Carbon-ion therapy remains confined to a handful of Japanese and German sites due to the high capital costs of approximately USD 80 million. Overall, software-centric upgrades dominate budgets as facilities extract more productivity from legacy hardware.
Complete Report Scope:
- By Therapy Type
- External Beam Radiotherapy (EBRT)
- Internal / Brachytherapy
- Systemic Radiotherapy
- By Technology
- Image-Guided Radiotherapy
- Intensity-Modulated Radiotherapy
- Stereotactic Radiosurgery
- Proton Beam Therapy
- 3D-Conformal Radiotherapy
- Volumetric Modulated Arc Therapy
- Other Technology
- By Application
- Breast Cancer
- Prostate Cancer
- Lung Cancer
- Head & Neck Cancer
- Central Nervous System / Brain
- Gastro-intestinal
- Other Applications
- By End User
- Hospitals & Clinics
- Speciality Clinics
- Ambulatory Surgery Centers
- Other End Users
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.52% of the radiotherapy market revenue in 2025. CMS outpatient parity led to a 22% increase in equipment orders during the first half of the year, primarily at urban freestanding sites. Canada added eight linacs under rural-access grants, while Mexico’s private sector expanded volume as insurance enrollment climbed. Utilization now reaches 68% of eligible U.S. patients, approaching the plateau of mature systems.The Asia-Pacific region is the fastest-growing, with a 9.01% CAGR. India’s USD 1.2 billion scheme to install 150 linacs aims to halve the nine-week waiting lists. Japan, South Korea, and Australia are bolstering reimbursement and workforce pipelines to support carbon-ion and proton services.
Europe accounts for 28% of revenue but faces budget constraints. Germany upgraded outpatient tariffs, shifting 18% of head-and-neck cases to day-clinic settings. The United Kingdom’s static tariff keeps proton reimbursements at 60% of cost, restraining private investment. France invested EUR 180 million to swap cobalt units for linacs, raising average dose conformality.
The Middle East and Africa together hold 6% share, dominated by Gulf Cooperation Council procurement. Saudi Arabia plans to finance eight linacs in 2025, aiming to reach four machines per million inhabitants by 2030. South America sits at a 4.5% share, with Brazil installing 12 linacs despite macroeconomic volatility.
List of Companies Covered in this Report:
- Accuray
- Becton Dickinson (BD)
- CDR Systems
- CIVCO Radiotherapy
- Eckert & Ziegler
- Elekta
- GE Healthcare
- Hitachi
- Ion Beam Applications SA
- IsoRay
- Klarity
- Mevion Medical Systems
- Mitsubishi Electric Corp.
- Nordion
- Orfit Industries
- ProTom International
- QIAGEN
- RaySearch Laboratories
- Sumitomo Heavy Industries
- Siemens Healthineers
- ViewRay Technologies
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accuray Incorporated
- Becton Dickinson (BD)
- CDR Systems
- CIVCO Radiotherapy
- Eckert & Ziegler
- Elekta AB
- GE Healthcare
- Hitachi Ltd.
- Ion Beam Applications SA
- Isoray Inc.
- Klarity
- Mevion Medical Systems
- Mitsubishi Electric Corp.
- Nordion Inc.
- Orfit Industries
- ProTom International
- Qfix
- RaySearch Laboratories
- Sumitomo Heavy Industries
- Siemens Healthineers AG
- ViewRay Technologies
